bioRxiv Science⌕ Search

Biology subjects

Sadek, A.

Publications and source records attributed to Sadek, A..

3 recordsLinked to original sources

Decoding Surface Fingerprints for Protein-Ligand Interactions

AO_SCPLOWBSTRACTC_SCPLOWSmall molecules have been the preferred modality for drug development and therapeutic interventions. This molecular format presents a number of advantages, e.g. long half-lives and cell permeability, making it possible to access a wide range of therapeutic targets. However, finding small molecules that engage "hard-to-drug" protein targets specifically and potently remains an arduous process, requiring experimental screening of extensive compound libraries to identify candidate leads. The search continues with further optimization of compound leads to meet the required potency and toxicity thresholds for clinical applications. Here, we propose a new computational workflow for high-throughput fragment-based screening and binding affinity prediction where we leverage the available protein-ligand complex structures using a state-of-the-art protein surface embedding framework (dMaSIF). We developed a tool capable of finding suitable ligands and fragments for a given protein pocket solely based on protein surface descriptors, that capture chemical and geometric features of the target pocket. The identified fragments can be further combined into novel ligands. Using the structural data, our ligand discovery pipeline learns the signatures of interactions between surface patches and small pharmacophores. On a query target pocket, the algorithm matches known target pockets and returns either potential ligands or identifies multiple ligand fragments in the binding site. Our binding affinity predictor is capable of predicting the affinity of a given protein-ligand pair, requiring only limited information about the ligand pose. This enables screening without the costly step of first docking candidate molecules. Our framework will facilitate the design of ligands based on the targets surface information. It may significantly reduce the experimental screening load and ultimately reveal novel chemical compounds for targeting challenging proteins.

bioinformatics↗

Neighbouring modifications interfere with the detection of phosphorylated alpha-synuclein at Serine 129: Revisiting the specificity of pS129 antibodies

Alpha-synuclein (aSyn) within Lewy bodies, Lewy neurites, and other pathological hallmarks of Parkinsons disease and synucleinopathies have consistently been shown to accumulate in aggregated and phosphorylated forms of the protein, predominantly at Serine 129 (S129). Antibodies against phosphorylated S129 (pS129) have emerged as the primary tools to investigate, monitor, and quantify aSyn pathology in the brain and peripheral tissues. However, most of the antibodies and immunoassays aimed at detecting pS129-aSyn were developed based on the assumption that neighbouring post-translational modifications (PTMs) either do not co-occur with pS129 or do not influence its detection. Herein, we demonstrate that the co-occurrence of multiple pathology-associated C-terminal PTMs (e.g., phosphorylation at Tyrosine 125 or truncation at residue 133 or 135) differentially influences the detection of pS129-aSyn species by pS129-aSyn antibodies. These observations prompted us to systematically reassess the specificity of the most commonly used pS129 antibodies against monomeric and aggregated forms of pS129-aSyn in mouse brain slices, primary neurons, mammalian cells and seeding models of aSyn pathology formation. We identified two antibodies that are insensitive to pS129 neighbouring PTMs. However, consistent with previous reports, most pS129 antibodies showed cross-reactivity towards other proteins and often detected low and high molecular weight bands in aSyn knock-out samples that could be easily mistaken for monomeric or High Molecular Weight aggregates of aSyn. Our observations suggest that the pS129 antibodies do not capture the biochemical and morphological diversity of aSyn pathology. They also underscore the need for more specific pS129 antibodies, more thorough characterization and validation of existing antibodies, and the use of the appropriate protein standards and controls in future studies.

neuroscience↗

Structural Insights of SARS-CoV-2 Spike Protein from Delta and Omicron Variants

Given the continuing heavy toll of the COVID-19 pandemic and the emergence of the Delta (B.1.617.2) and Omicron (B.1.1.529) variants, the WHO declared both as variants of concern (VOC). There are valid concerns that the latest Omicron variant might have increased infectivity and pathogenicity. In addition, the sheer number of S protein mutations in the Omicron variant raise concerns of potential immune evasion and resistance to therapeutics such as monoclonal antibodies. However, structural insights that underpin the potential increased pathogenicity are unknown. Here we adopted an artificial intelligence (AI)-based approach to predict the structural changes induced by mutations of the Delta and Omicron variants in the spike (S) protein using Alphafold. This was followed by docking the human angiotensin-converting enzyme 2 (ACE2) with the predicted S proteins for Wuhan-Hu-1, Delta, and Omicron variants. Our in-silico structural analysis indicates that S protein for Omicron variant has a higher binding affinity to ACE-2 receptor, compared to Wuhan-Hu-1 and Delta variants. In addition, the recognition sites of the receptor binding domains for Delta and Omicron variants showed lower electronegativity compared to Wuhan-Hu-1. Importantly, further molecular insights revealed significant changes induced at fusion protein (FP) site, which may mediate enhanced viral entry. These results represent the first computational analysis of structural changes associated with Omicron variant using Alphafold, Collectively, our results highlight potential structural basis for enhanced pathogenicity of the Omicron variant, however further validation using X-ray crystallography and cryo-EM are warranted.

biophysics↗